Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Vanguard Total International Bond Index Fund ETF (BNDX) vs Pfizer Inc (PFE) Price & Performance

Vanguard Total International Bond Index Fund ETFTrade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

Vanguard Total International Bond Index Fund ETF vs Pfizer Inc — how do they compare? Vanguard Total International Bond Index Fund ETF trades at $47.99, while Pfizer Inc trades at $24.56 (market cap $138.21B). The key difference: Pfizer Inc pays a 7.09% dividend while Vanguard Total International Bond Index Fund ETF pays none. Which is the better fit depends on your goals.

BNDXPFE
52-Week High
$49.91$28.56
52-Week Low
$47.57$23.29
Market Cap
$138.21B
Volume
29,869,932
Sector
Health
Enterprise Value
$188.87B
Dividend Yield
7.09%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Vanguard Total International Bond Index Fund ETF

BNDX trades at $47.89, down 0.4% with a bearish technical signal from moving averages. The ETF shows neutral momentum oscillators but faces pressure from rising bond yields and Fed uncertainty. Recent news highlights strong bond ETF inflows as investors seek yield amid market volatility, though inflation concerns persist.

Outlook remains cautious due to potential Fed rate hikes and macroeconomic headwinds. The fund offers steady income through dividends but faces valuation pressure from rising rates. Key risks include interest rate sensitivity and global economic shifts impacting international bond performance.

Pfizer Inc

Pfizer (PFE) trades at $24.48, up 1.28% on the day, with a bearish technical signal from moving averages but neutral oscillators. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $0.75 surpassing the $0.722 estimate. The company maintains solid profitability with a 73.51% gross margin and 11.83% net margin, while cash flow trends show positive net cash generation in 2025. News highlights focus on Pfizer's pipeline developments in obesity and oncology therapies.

The stock presents a value opportunity with a P/E of 18.51 below industry averages and a consensus price target of $28.78 implying 18% upside. However, risks include patent expirations, competitive pressures, and debt levels near 31% of assets. Analyst sentiment is mixed with 38% buy ratings versus 59% hold, suggesting cautious optimism amid pipeline execution uncertainties.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Vanguard Total International Bond Index Fund ETF

The fund employs an indexing investment approach designed to track the performance of the Bloomberg Global Aggregate ex-USD Float Adjusted RIC Capped Index (USD Hedged). This index provides a broad-based measure of the global, investment-grade, fixed-rate debt markets. It is non-diversified.

Read more on BNDX

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE